A no-deal Brexit could mean drug companies delay plans to bring new medicines to the UK, according to a Whitehall report on the potential impact of a no-deal departure. It said pharmaceutical firms could delay their applications for a UK licence by three months after applying for similar clearance in the EU. The report said the companies currently waited an average of up to a year between applying for EU clearance and for permission in countries that had their own licensing rules, as the UK would have after Brexit. In 10% of cases that delay stretched to a year.
A no-deal Brexit could mean drug companies delay plans to bring new medicines to the UK, according to a Whitehall report on the potential impact of a no-deal departure. It said pharmaceutical firms could delay their applications for a UK licence by up to a year after applying for similar clearance in the EU. The report said the companies currently waited an average of three months between applying for EU clearance and for permission in countries that had their own licensing rules, as the UK would have after Brexit. In 10% of cases that delay stretched to a year.